JP2019519536A - Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法 - Google Patents

Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法 Download PDF

Info

Publication number
JP2019519536A
JP2019519536A JP2018562626A JP2018562626A JP2019519536A JP 2019519536 A JP2019519536 A JP 2019519536A JP 2018562626 A JP2018562626 A JP 2018562626A JP 2018562626 A JP2018562626 A JP 2018562626A JP 2019519536 A JP2019519536 A JP 2019519536A
Authority
JP
Japan
Prior art keywords
gitr
antibody
seq
tumor
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519536A5 (enExample
Inventor
フォイ スーザン
フォイ スーザン
ブレナン トーマス
ブレナン トーマス
ケラー ダニエル
ケラー ダニエル
Original Assignee
ファイブ プライム セラピューティクス， インコーポレイテッド
ファイブ プライム セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイブ プライム セラピューティクス， インコーポレイテッド, ファイブ プライム セラピューティクス， インコーポレイテッド filed Critical ファイブ プライム セラピューティクス， インコーポレイテッド
Publication of JP2019519536A publication Critical patent/JP2019519536A/ja
Publication of JP2019519536A5 publication Critical patent/JP2019519536A5/ja
Priority to JP2022000978A priority Critical patent/JP2022058518A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018562626A 2016-07-01 2017-06-30 Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法 Pending JP2019519536A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000978A JP2022058518A (ja) 2016-07-01 2022-01-06 Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357750P 2016-07-01 2016-07-01
US62/357,750 2016-07-01
PCT/US2017/040259 WO2018005950A1 (en) 2016-07-01 2017-06-30 Combined anti tumor therapy with a gitr agonist and cpg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000978A Division JP2022058518A (ja) 2016-07-01 2022-01-06 Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法

Publications (2)

Publication Number Publication Date
JP2019519536A true JP2019519536A (ja) 2019-07-11
JP2019519536A5 JP2019519536A5 (enExample) 2020-07-27

Family

ID=59363240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562626A Pending JP2019519536A (ja) 2016-07-01 2017-06-30 Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
JP2022000978A Pending JP2022058518A (ja) 2016-07-01 2022-01-06 Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022000978A Pending JP2022058518A (ja) 2016-07-01 2022-01-06 Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法

Country Status (5)

Country Link
US (1) US20190263919A1 (enExample)
EP (1) EP3478721A1 (enExample)
JP (2) JP2019519536A (enExample)
CN (1) CN109641967A (enExample)
WO (1) WO2018005950A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992298A1 (en) * 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
WO2022036013A1 (en) * 2020-08-11 2022-02-17 Exicure Operating Company Tumor necrosis factor receptor superfamily (tnfrsf) agonists, spherical nucleic acid (sna) tlr9 agonists and checkpoint inhibitors for antitumor therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015623A2 (en) * 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
CA2586913A1 (en) * 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
KR101853702B1 (ko) 2009-12-07 2018-05-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 항-종양 항체 치료를 향상시키는 방법
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
HK1258509A1 (zh) 2015-10-22 2019-11-15 Ablynx Nv Gitr激动剂
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015623A2 (en) * 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROCH HOUOT AND RONALD LEVY: "T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need fo", BLOOD, vol. VOLUME 113, NUMBER 15, JPN6021020952, 2009, pages 3546 - 3552, ISSN: 0004721450 *

Also Published As

Publication number Publication date
US20190263919A1 (en) 2019-08-29
JP2022058518A (ja) 2022-04-12
EP3478721A1 (en) 2019-05-08
WO2018005950A1 (en) 2018-01-04
CN109641967A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
US12435136B2 (en) Antibodies binding to ILT4
US20220298258A1 (en) PSGL-1 Antagonists and Uses Thereof
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
ES2857076T3 (es) Terapia de combinación para cáncer
KR20180031728A (ko) 다가 및 다중특이적 gitr 결합 융합 단백질
JP2022058518A (ja) Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
KR20190139216A (ko) Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
KR20230154981A (ko) 항-인간 cxcr5 항체 및 이의 용도
JP2020512357A (ja) 抗ｇｉｔｒ抗体を使用した癌の併用療法
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
EA039894B1 (ru) Способ лечения рака, композиция для лечения рака, применение композиции для получения лекарственного средства для лечения рака, характеризующегося присутствием макрофагов, экспрессирующих csf1r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308